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Abstract 
Temporal lobe epilepsy is a common, chronic neurologic disorder characterized by recurrent 
spontaneous seizures. MicroRNAs (miRNAs) are small, non-coding RNAs that regulate post-
transcriptional expression of protein-coding mRNAs, which may have important roles in the 
pathogenesis of neurologic disorders. In models of prolonged, injurious seizures (status 
epilepticus) and in experimental and human epilepsy, we found up-regulation of miR-134, a brain-
specific, activity-regulated miRNA implicated in the control of dendritic spine morphology. 
Silencing of miR-134 expression in vivo using antagomirs reduced hippocampal CA3 pyramidal 
neuron dendrite spine density by 21%, and rendered mice refractory to seizures and hippocampal 
injury caused by status epilepticus. Depletion of miR-134 after status epilepticus reduced the later 
occurrence of spontaneous seizures by over 90% and mitigated attendant pathologic features of 
temporal lobe epilepsy. Thus, silencing miR-134 exerts prolonged seizure suppressant and 
neuroprotective actions; whether these represent anticonvulsant or truly antiepileptogenic effects 
requires additional experimentation. 
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Epilepsy is a serious, chronic neurologic disorder characterized by recurrent spontaneous 
seizures which affects about 50 million people worldwide. Anti-epileptic drugs typically 
control seizures in two-thirds of patients but probably do not alter the underlying 
pathophysiology1. The development of symptomatic (acquired) epilepsy is thought to 
involve altered expression of ion channels, synaptic remodeling, inflammation, gliosis and 
neuronal death, among others2-5. However, few anti-epileptogenic interventions targeting 
these processes have shown sufficient efficacy in vivo1, and our understanding of the cell 
and molecular mechanisms remains incomplete. 
Evidence is emerging that microRNAs (miRNAs) may be critical to the pathogenesis of 
several neurologic disorders6-7, including epilepsy8-9. MiRNAs are a family of small (~22 
nt), endogenously expressed non-coding RNAs that regulate mRNA translation by imperfect 
base-pairing interactions within the 3 ' untranslated region10-11. Depending on the degree of 
sequence complementarity, miRNA binding, which occurs via Argonaute proteins within the 
RNA-induced silencing complex (RISC), results in either cleavage or a reduction in the 
translational efficiency of the target mRNA10-11. 
MiR-134 is a brain-specific, activity-regulated miRNA implicated in the control of neuronal 
microstructure12-13. Pyramidal cells are the most common neurons in the neocortex and 
hippocampal formation2. They are the major source of intrinsic excitatory cortical synapses, 
and their dendritic spines are the main postsynaptic target of excitatory synapses, with spine 
size an index of synaptic strength14-16. Spine remodeling occurs during learning and 
memory formation, and in the setting of neuropsychiatric disorders and pathological brain 
activity17-21. Spine collapse is mediated in part by TV-methyl-D-asparate (NMD A) receptor 
and calcium-dependent de-polymerization of actin by cofilin19'22-23. LIM kinase-1 (Limkl) 
phosphorylates and inactivates cofilin and loss of Limkl results in abnormal spine 
morphology24. In hippocampal neurons, miR-134 targets Limkl mRNA, thereby preventing 
Limkl protein translation13. Over-expression of miR-134 in vitro has been reported to 
reduce spine volume13, whereas over-expression of miR-134 in vivo reduces total dendritic 
length25 and abrogates long-term potentiation26. Mice lacking the miRNA biogenesis 
component DiGeorge syndrome critical region gene 8 fail to produce several mature 
miRNAs, including miR-134, and display reduced hippocampal spine density27. Spine loss 
may have divergent consequences according to context28, promoting excitability29 or 
uncoupling NMDA receptor-driven currents in neurons and preventing excitotoxicity30. 
Here we investigated the role of miR-134 in epilepsy and explored the in vivo effect of 
inhibiting miR-134. We report that miR-134 is up-regulated in experimental and human 
epilepsy and show that silencing miR-134 generates a seizure-refractory state and attenuates 
epileptic seizures and pathophysiological features of temporal lobe epilepsy (TLE). 
Results 
MiR-134 is regulated by status epilepticus and in epilepsy 
We first investigated whether pathologic brain activity in vivo affects miR-134 levels. 
Prolonged seizures (status epilepticus, SE) were triggered by intra-amygdala microinjection 
of the glutamate receptor agonist kainic acid (KA) in mice31-32. The resultant seizures 
caused neuronal damage mainly within the hippocampal CA3 subfield (Fig. la) and 
triggered the later emergence of recurrent spontaneous (i.e. epileptic) seizures (Fig. If)31. 
To identify the cell populations expressing miR-134 in vivo we used in situ hybridization. 
Tissue sections labeled with a probe specific for mature miR-134 detected a strong signal in 
the soma of hippocampal pyramidal neurons and hilar intemeurons, as well as neurons in the 
neocortex and amygdala (Fig. lb and Supplementary Fig. 1). 
Real-time quantitative PCR (RT-qPCR) analysis showed SE resulted in an increase in 
mature miR-134 levels in the ipsilateral CA3 and CA1 subfields (Fig. lc). Mature miR-134 
levels were not changed in the undamaged contralateral CA3 (Supplementary Fig. 2a). Non-
harmful, non-convulsive seizures, a model of epileptic preconditioning33 in which SE does 
not develop, did not alter miR-134 levels compared to control in CA3 (P= 0.89) or CA1 (P 
= 0.56) (n= 6 per group, data not shown). 
To determine whether miR-134 was functional, we measured levels within the RISC, where 
targeting of miRNAs to mRNA occurs34. Argonaute-2 was eluted from CA335~36 and 
miRNA extracted. A low level of miR-134 was detected in the RISC in controls, whereas 
levels of Argonaute-2-bound miR-134 were higher after SE (Fig. Id). Protein levels of the 
miR-134 target, Limkl13, were significantly lower in mice after SE (Fig. le). 
We next investigated whether miR-134 and Limkl expression was altered in experimental 
epilepsy. Spontaneous seizures emerge 3-4 days after SE in the present model31'33 and 
within weeks animals display pathologic hallmarks of TLE, including neuron loss and 
astrogliosis (Fig. If). miR-134 levels were elevated one and three weeks after SE in CA1 
and after three weeks in the CA3 of epileptic mice (Fig. lg). Limkl protein levels followed 
an opposite trend, being decreased in epileptic animals (Fig. lh). Levels of Crebl, another 
validated miR-134 target26, were also lower in epileptic mice (Supplementary Fig. 2b). 
We next undertook an analysis of temporal lobe material from individuals with 
pharmacoresistent TLE. Higher levels of mature miR-134 were detected in TLE specimens 
compared to autopsy controls (Fig. li). This difference was not an artifact of post-mortem 
delay (Supplementary Fig. 2c-e). Protein levels of LIMK1 were lower in individuals with 
TLE compared to autopsy controls (Fig. li). 
In vivo depletion of miR-134 using antagomirs 
To explore the function of miR-134 in vivo, we injected mice with locked nucleic acid 3 ' 
cholesterol-conjugated oligonucleotides ("antagomirs")36-39- Antagomirs targeting miR-134 
(Ant-134) (Supplementary Fig. 3a) or a non-targeting scrambled sequence (Scr) were 
injected into the mouse ventricle (i.c.v.) (Supplementary Fig. 3b) and miRNA levels 
measured 1, 4, 8 or 12 h later, and after 1, 3, 5, 7 days, 1 and 2 months. A significant 
knockdown of miR-134 was first evident 12 h after injection of 0.12 nmol Ant-134 
(Supplementary Fig. 4a-d), and by 24 h hippocampal levels of miR-134 were reduced by 
over 95% (Fig. 2a). This is similar to effects reported for antagomirs in other tissues37. 
Hippocampal levels of an unrelated miRNA, miR-19a, were not changed (Fig. 2b). 
Increasing the injected amount to 1 nmol appeared to produce off-target knockdown of 
miRNAs (Supplementary Fig. 4e,f). Levels of miR-134 began to recover by 7 days after 
Ant-134 injection although remained lower at 1 month, consistent with other reports37, and 
had recovered by 2 months (Fig. 2c). 
Brains from mice injected with antagomirs had grossly normal anatomy (data not shown). 
No evidence of hippocampal neuronal death was found when sections from mice injected 
with antagomirs were stained for Fluoro-Jade B (FJB), DNA fragmentation (terminal 
deoxynucleotidyl dUTP nick end labeling; TUNEL)40, and the neuronal marker NeuN (Fig. 
2d,e and data not shown). 
To determine if reduction in the levels of miR-134 had any gross effects on animal behavior 
we performed ethological tests41. Mice were injected with either Scr or Ant-134 and 
assessed 24 h later. No differences in ambulatory counts, distance travelled or vertical 
counts were found between groups (Fig. 2f), suggesting silencing of miR-134 does not alter 
normal exploratory activities. 
miR-134 antagomirs reduce pyramidal neuron spine density 
Because in vitro and in vivo evidence supports a role for miR-134 in controlling dendritic 
spine morphology13'25'27, we examined whether antagomirs caused changes to dendritic 
spines in vivo. Individual CA3 pyramidal neurons in hippocampal slices from mice given 
0.12 nmol Ant-134 or Scr 24 h earlier were microinjected with Lucifer Yellow and imaged 
using confocal microscopy, as described42-43 (Fig. 3a, b). 
Two-hundred eighteen neurons in Scr mice (n= 7) and 181 neurons in Ant-134 mice (n= 7) 
were analyzed. The structure of the basal dendritic tree was grossly normal between groups, 
as was the distribution of spines (Fig. 3c, e). Dendrites from Scr mice had an average of 68 
nodes (ramifications) compared to 72 nodes in Ant-134 animals. The number of ramification 
points per |xm was also similar (0.0127 nodes per |xm in Scr compared to 0.0131 nodes per 
|xm in Ant-134). We then analyzed spine density, assessing a total of 5343.7 |xm length of 
dendrites in Scr mice (7455 spines) and a similar length (5477.5 |xm) in Ant-134 animals 
(6196 spines). Spine density in Scr-injected animals was within the expected range42 (Fig. 
3d-f). Surprisingly, spine density was 21% lower in Ant-134 mice (Fig. 3d-f). Thus, 
injecting miR-134 antagomirs in vivo result in a significant reduction of spine density. 
Silencing miR-134 inhibits SE and resultant neuronal death 
To test the idea that antagomirs might influence pathologic brain activity in vivo, we 
compared seizures evoked by intra-amygdala KA between mice injected 24 h earlier with 
either Scr or Ant-134 (Fig. 4a and see Supplementary Fig. 3c). There was no difference in 
basal EEG between groups (Supplementary Fig. 5a). Scr-injected mice experienced typical 
SE, comprising episodes of high amplitude high frequency discharges (HAHFDs)44 
(compare Fig. 4c to Fig. la). EEG analysis revealed the duration of HAHFDs, which are 
associated with damage-causing pathologic activity45, and total EEG power, were strongly 
reduced in Ant-134-injected mice (Fig. 4a-c). This effect was qualitatively similar to seizure 
suppression observed in animals given lorazepam 10 min before KA (compare Fig. 4c to 
Supplementary Fig. 5b). 
miR-134 levels were reduced in mice injected with Ant-134 prior to intra-amygdala KA 
compared to Scr-treated animals (Fig. 4d and Supplementary Fig. 6a). Limkl protein levels 
(Fig. 4e) and levels of Crebl (Supplementary Fig. 6b) were lower after SE in Scr-injected 
mice, whereas levels of both were higher and similar to controls in animals injected with 
Ant-134 before KA. 
We next examined hippocampal damage in tissue sections from Scr and Ant-134 mice. Scr-
injected mice displayed typical CA3 lesions 24 h after SE, with extensive staining of 
neurons for FJB and TUNEL, and loss of NeuN staining (Fig. 5a-f). Mice injected with 
Ant-134 showed a dramatic reduction in each measure of seizure-induced neuronal death 
(Fig. 5a-f). 
To specifically link the neuroprotective effects of antagomirs to miR-134 and Limkl, 
cultures of primary hippocampal neurons were treated with KA to model excitotoxic injury. 
Treatment with KA increased miR-134 levels (Fig. 5g). Ant-134 prevented KA-induced 
neurotoxicty in hippocampal neurons, and this was blocked in neurons transfected with 
short-hairpin RNAs targeting Limkl (Fig. 5h-j). 
Silencing miR-134 reduces spontaneous recurrent seizures 
On the basis of findings so far, we hypothesized that silencing miR-134 might also affect 
epilepsy. To avoid a confounding influence of shortened SE duration or neuroprotection on 
epileptogenesis40'46, we injected antagomirs 1 h after triggering SE. Analysis of EEG 
confirmed that when antagomirs were injected 1 h after KA, there was no difference in SE 
between Ant-134 and Scr groups (Fig. 6a). Also, CA3 damage assessed 24 h later was 
similar between Ant-134 and Scr animals (Fig. 6b,c). 
We then equipped groups of mice with EEG telemetry units31 and undertook continuous 24 
h per day EEG recording for two weeks following SE. In agreement with the normal course 
of epilepsy in this model31, mice injected with Scr after SE experienced the first 
spontaneous seizures on the third day, and all mice were epileptic by the fourth day (Fig. 
6d,e and Supplementary Fig. 6c). The median epileptic seizure count for Scr-injected mice 
was 25 (range 8-79), with 200 epileptic seizures recorded in total (Fig. 6d and 
Supplementary Fig. 6c). In contrast, only 60% of mice injected with Ant-134 had had a 
spontaneous seizure by the 11th day after SE (Fig. 6d and Supplementary Fig. 6c); one 
mouse had only a single seizure on day 14, and another had no seizures (Fig. 6d). Ant-134-
injected mice had a median epileptic seizure count of 2 (range 0-7), with just 16 epileptic 
seizures in total during the two week recording period (P= 0.0001, two-way ANOVA 
compared to Scr group) (Fig. 6e). The total amount of time spent in seizures also differed 
between groups (P< 0.001, two-way ANOVA, Supplementary Fig. 6c). The duration of 
individual epileptic seizures was similar between groups (Supplementary Fig. 6d). 
Silencing miR-134 alters pathologic hallmarks of TLE 
Progressive neuron loss, gliosis and rearrangement of mossy fibers are common pathological 
hallmarks of TLE47^8. Next, we examined whether Ant-134 had altered underlying 
pathology in the telemetry mice. Neuron counts in Ant-134-injected mice were higher than 
in Scr-treated animals at the end of epilepsy monitoring and astrogliosis was reduced (Fig. 
6f). Neuropeptide Y (NPY) staining, an index of increasing reorganization of the 
hippocampus33'49, in Scr-treated mice (Fig. 6g), was similar to previously reported scores in 
epileptic mice33 whereas NPY scores in Ant-134 mice were significantly lower (Fig. 6g). 
To investigate whether the reduced epileptic seizure rates were due to an anti-epileptogenic 
effect or a prolonged anticonvulsant effect of Ant-134, we performed additional 
experiments. First, we measured miR-134 levels in Ant-134 mice at the end of 14 days of 
telemetry recordings, which established levels were -55% of those in Scr-injected animals 
(Supplementary Fig. 7a). Modeling this miR-134 reduction in mice did not produce an 
anticonvulsant effect against KA-induced SE (Supplementary Fig. 7b, c). Likewise, when 
Ant-134 was injected 14 days before KA this reduced levels of miR-134 to -70% of Scr but 
mice were normally sensitive to KA-induced SE (Supplementary Fig. 7e-h), and animals 
were not protected against SE-induced damage (Supplementary Fig. 7i,j). Finally, longer-
term video monitoring revealed mice given Ant-134 after SE displayed fewer generalized 
tonic-clonic seizures and more seizure-free days up to two months later compared to Scr-
injected animals, although seizure rates did increase in 3 out of 5 animals (Fig. 6h,I and 
Supplementary Fig. 8). 
Discussion 
Our study shows silencing miR-134 in mice using antagomirs profoundly suppresses evoked 
seizures, the occurrence of spontaneous seizures and associated pathologic hallmarks of 
epilepsy. These are the first in vivo data to show that inhibition of a single mature miRNA 
can alter pathologic electrical activity in brain and they offer a novel therapeutic target for 
the treatment of epilepsy. 
An association between seizures and changes to miRNA expression has been suggested by 
recent profiling work8-9'36'50, and by the phenotype of mice lacking Dicer51, although our 
experiments are the first to link up-regulation of miR-134 to evoked, harmful seizures and 
chronic epilepsy. Brief, non-harmful generalized seizures were insufficient to alter miR-134 
expression. This suggests in vivo regulation of miR-134 is not only a response to increased 
neuronal activity13, but is coupled to epileptic or pathogenic brain activity. Critically, 
miRNA silencing experiments here support a role for miR-134 in facilitating pathologic 
neuronal activity in vivo because SE was potently suppressed in animals in which miR-134 
was depleted by antagomirs. Notably, the seizure-suppressing effect of the antagomirs was 
nearly comparable to benzodiazepines45-46'52. Injecting antagomirs before SE also protected 
against seizure-damage. This probably arises because of shortened seizure duration46'52 but 
antagomirs inhibited direct KA toxicity in vitro. Our in vitro experiments also implicated 
Limkl in the mechanism of protection, but rescuing Crebl levels may also contribute53 and 
our data are consistent with the neuroprotective effect of sirtuin 1, which negatively 
regulates miR-134 expression in brain26. 
Despite progress in understanding the pathogenesis of epilepsy, few studies targeting 
epileptogenic processes have shown sufficient efficacy at reducing the occurrence, course or 
severity of the disease1'54. A second major finding here was that silencing miR-134 after SE 
resulted in a very substantial reduction of epileptic seizures in mice. Epilepsy developed 
normally in Scr-injected mice31, whereas spontaneous seizures seldom occurred in Ant-134-
treated animals. Thus, the effect was superior to neuroprotection applied at the time of 
SE40'55 and comparable or exceeds the performance of other experimental anti-epileptogenic 
treatments1. Did the antagomirs interrupt epileptogenesis or simply prevent epileptic 
seizures from occurring due to a prolonged anticonvulsant effect or in a manner similar to 
anti-epileptic drugs? Spontaneous seizures were detected, albeit infrequently, and the 
increase in seizure rates over extended monitoring supports the interpretation of a prolonged 
anticonvulsant or anti-epileptic effect. Nevertheless, seizure rates never recovered to 
baseline and seizure frequency two months after SE, a time when antagomir suppression of 
miR-134 was no longer significant, was over 70% lower so an anti-epileptogenic effect 
remains possible. Additional experiments examining seizure frequency at time points later 
than two months will be required to distinguish these possibilities. 
The mechanism by which miR-134 antagomirs suppressed seizures is unknown but our 
study offers the intriguing possibility that the effect is via changes to dendritic spines. The 
finding that Ant-134 reduced hippocampal CA3 dendritic spine density in vivo was 
surprising, and contrasts reports that spine size, not density, was controlled by miR-13413. 
Thus, a different phenotype results from miR-134 inhibition in vivo, which may be 
explained by the scale of miRNA suppression achieved, distribution of antagomir (somal 
versus dendritic), targets affected or potency of LNA-modified antagomirs over 2 ' -0-
methyl-oligonucleotides39. Coincidently, a similar reduction in spine density was reported in 
mice lacking a miRNA biogenesis component, in which hippocampal levels of mature 
miR-134 were also reduced27. A key target of miR-134 is Limkl, which regulates dendritic 
spine dynamics13. Limkl protein levels followed an opposite pattern to miR-134 expression 
and miR-134 silencing prevented seizure-induced down-regulation of Limkl, although other 
explanations for a decrease in spines are possible15'56. Could the reduction in spines account 
for seizure-suppression? Dendritic spines are targets of excitatory axons in the brain14-15. 
Although spines have been suggested to operate as barriers against potentially harmful 
afferent input28, our data are consistent with evidence showing spine loss reduces excitatory 
responses17'57, and transient spine reduction uncouples excitotoxic NMDA-mediated 
signaling30. The antagomirs appear to curtail pathologic activity in brain without impairing 
tonic neuronal communication; this would have been detected by the ethogram, and is 
consistent with reports that a -20% reduction in hippocampal pyramidal neuron spine 
numbers does not alter basal neurotransmission58. Spine-localized synaptic signaling is also 
implicated in the pathogenesis of TLE3, but whether a similar mechanism may account for 
the seizure suppressant effects of miR-134 silencing is unknown. Loss of Limkl, which was 
countered via antagomirs, can result in increased hippocampal excitability24. However, 
other miR-134 targets with effects on excitability and seizure suppression are known26'53. 
While therapeutic application of miR-134 antagomirs for SE is probably barred by a need 
for pre-treatment, the longevity of the suppression after a single injection, consistent with 
antagomir data from mouse and primate experiments37'39, suggests applications in refractory 
epilepsy or disease-modification in the wake of epilepsy-precipitating injuries. Alternate 
routes for antagomir deliver such as intra-nasal, as considered for anti-epileptic drug 
delivery59, may avoid blood brain barrier exclusion of antagomirs in vivo''1', and facilitate 
translation to the clinic for the treatment of epilepsy. 
ONLINE METHODS 
Seizure models 
All animal experiments were performed in accordance with the European Communities 
Council Directive (86/609/EEC) and were reviewed and approved by the Research Ethics 
Committee of the Royal College of Surgeons in Ireland (REC #205), under license from the 
Department of Health, Dublin, Ireland. Adult (20-22 g) male C57BL/6 mice (Harlan) were 
purchased from Harlan. Food and water was available ad libitum. Induction of SE was 
performed as described previously31. Mice were anesthetized with isoflurane and placed in a 
mouse-adapted stereotaxic frame. Following a midline scalp incision, Bregma was located 
and three partial craniectomies performed for placement of skull-mounted recording screws 
(Bilaney Consultants). A fourth craniectomy was drilled for placement of a guide cannula 
(Coordinates from Bregma; AP = -0.94 mm, L = -2.85 mm) based on a stereotaxic atlas60. 
The cannula and electrode assembly was fixed in place and the animal placed in an open 
Perspex box which allowed free movement. The EEG was recorded using a Grass Comet 
digital EEG. After baseline EEG was established, the animal was lightly restrained while an 
injection cannula was lowered 3.75 mm below the brain surface for injection of KA (Sigma-
Aldrich) or vehicle (phosphate-buffered saline (PBS), pH adjusted to 7.4) into the 
basolateral amygdala nucleus. After 40 min, all mice received lorazepam (Ativan, 6 mg 
kg -1, i.p.). Animals were recorded for up to an hour thereafter before being disconnected 
and placed in a warmed recovery chamber. Non-harmful seizures were induced by a single 
injection (i.p.) of KA (15 mg kg-1), as described36. 
EEG analysis during SE 
EEG was analyzed using TWinR software and the duration of HAHFDs, also termed as type 
IV seizures, was calculated between the time of KA injection and the time of lorazepam 
administration by an observer blinded to treatment group. Additional frequency and 
amplitude analysis of EEG was performed by uploading data to an automated programme 
for EEG analysis (LabChart Pro v7 software, AD Instruments Ltd). 
Intracerebroventricular injections 
For i.c.v. injections, additional mice were affixed with a cannula ipsilateral to the side of KA 
injection. Coordinates from Bregma were: AP = -0.3 mm, L = -1.0 mm, V = -2.0 mm. 
Mice received 1 |xL infusion of either Scr or Ant-132 LNA- and 3'-cholesterol modified 
oligonucleotides (Exiqon) in aCSF (Harvard Apparatus). Mice were either euthanized or 
underwent SE. For experiments involving intranasal administration of antagomirs, 0.12 
nmol of scramble or antagomir in a 5 |xl volume was administrated into each nostril of the 
mice. Mice were euthanized at various time points after antagomirs (1, 4, 8, 12 or 24 h, and 
3,5,7, 14, 28 days and 2 months), after KA or vehicle (24 h), or once animals began to 
display spontaneous seizures at 1, 2, 4 or 8 weeks after intra-amygdala injections. 
Analysis of spontaneous seizures using EEG telemetry 
Epilepsy monitoring via implanted EEG telemetry units was performed as previously 
described55. EEG data were acquired with EEG transmitters (Model:F20-EET, Data 
Systems International) configured to record 2-channel EEG that were skull-affixed over 
dorsal hippocampi and temporal cortex under anaesthesia at the time of surgery for intra-
amygdala injection. Transmitter units were placed in a subcutaneous pocket along the dorsal 
flank. Continuous (24 h per day) EEG data were collected for 14 consecutive days after SE. 
EEG data were reviewed and manually scored by an observer unaware of experimental 
treatment with epileptic seizures defined as high frequency (>5 Hz) high amplitude (>2 x 
baseline) polyspike discharges of >5 s duration. 
Analysis of spontaneous seizures by continuous video monitoring 
Mice were subjected to intra-amygdala KA-induced SE and then injected 1 h later with Scr 
or Ant-134 i.c.v., as before. Animals were allowed to recover and then housed in pairs (mice 
distinguished by ear clips) in clear Perspex cages (dimensions: 32 cm (long) x 17 cm (wide) 
x 14 cm deep). Webcam-style cameras connected to laptop computers were placed 40 cm 
from cages in a room equipped with safe lights for night-time recordings. Images were 
captured using VirtualDub 1.9.11 (SourceForge.net) with a sampling rate of 10 frames per 
second and data transfer rate of 140 kb s_1. Videos from five days continuous (24 h per day) 
monitoring periods during weeks 3-4 and weeks 7-8 post-SE were reviewed by an observer 
unaware of experimental treatment. Seizures were counted using a modified 6-point Racine 
scale for mice. Score 2, Forelimb and or tail extension, rigid posture; 3, repetitive 
movements, head bobbing; Score 4, rearing and falling; Score 5, continuous rearing and 
falling; Score 6, severe tonic-clonic seizures. Note, clinical events below Score 2 (i.e. Score 
1) such as sudden freezing and immobility were not included. The numbers of seizures per 
day was analyzed using Poisson regression with robust standard errors in order to express 
the experimental effect as an incidence rate ratio. Average Racine score and number of 
seizure-free days were compared using the Wilcoxon Mann-Whitney test. 
Mouse tissue samples 
Mice were killed by pentobarbital overdose and perfused with ice-cold saline to remove 
intravascular blood components. Brains for molecular and biochemical work were 
microdissected over wet ice with the hippocampus further sub-divided to obtain the separate 
CA3-enriched portion as described55. For histology, mice were either perfusion fixed with 
paraformaldehyde (4%) or brains fresh-frozen in 2-methylbutane (at -30 °C). 
Human samples 
This study was reviewed and approved by the Beaumont Hospital Ethics (Medical Research) 
Committee (approval REC 05/18) and informed consent was obtained from each subject. 
Subjects (iz=3) were determined to have medically intractable TLE and had been referred 
by an epileptologist (N.D.) for surgical resection of the temporal lobe (D. O'B) following 
neurological assessment, video-EEG recording and neuroimaging (magnetic resonance 
imaging). All patients were taking antiepileptic drugs prior to surgery. Each temporal lobe 
neocortex sample was inspected by a pathologist (M.F.) and deemed absent any obvious 
neuron loss or lesion. Subject 1 was a 27 year old male who underwent right posterior 
temporal lobectomy. Subject 2 was a 53 year old male who underwent right anterior 
temporal lobectomy. Subject 3 was a 45 year old male who underwent temporal lobectomy. 
Temporal neocortex samples were flash-frozen in liquid nitrogen and stored at -70 °C until 
use. The sample was divided and used for either miRNA measurement or protein analysis. 
Human control samples were also fresh-frozen and donated by people who died of causes 
not related to known neurological disease and obtained from the Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland, Baltimore, Maryland, USA. 
Samples were all from people of Caucasian race (Mean age 26.3 years, range 25 - 28). 
Causes of death were (for CI, C2) multiple injuries from road traffic accident, and (C3) 
cardiac tamponade. The average autopsy delay was 6.7 h (range 7-12 h). 
Simulated post mortem delay 
To simulate postmortem delay, mice were killed and cortices from the temporal association 
region extracted either immediately (0 h), or removed after a delay of 6 h or 12 h (simulated 
postmortem interval). Samples were then processed for miRNA measurement. 
Histopathology 
Coronal sections from two levels of dorsal (septal) hippocampus were analyzed (rostral, AP 
= -1.46 mm; medial, AP = -1.70 mm). For detection of neurodegeneration, sections were 
stained using FJB55 (Millipore). Irreversible DNA damage was detected by Fluorescein-
based TUNEL kit (Promega). For immunohistochemistry, sections were post-fixed, 
permeabilized, blocked in 5% goat serum and then incubated overnight with antibodies 
against NeuN (1:400, Clone A60, Millipore), GFAP (1:400, G9269) orNPY (1:1,000, 
N9528) (both from Sigma-Aldrich). Sections were washed and incubated with secondary 
antibodies raised in goat conjugated with AlexaFluor 488 (for NeuN) or AlexaFluor 568 (for 
GFAP and NPY) (BioSciences Ltd). Sections were mounted with medium containing 4',6 
diamidino-2-phenylindole (DAPI) (Vector Laboratories Ltd). Sections were examined using 
a Hamamatsu Orca 285 camera attached to a Nikon 2000s epifluorescence microscope 
(Micron-optical). Counts were the average of two adjacent sections of the ipsilateral CA3 
subfield scored by an observer blinded to experimental treatment. 
Synaptic reorganization was assessed blinded to experimental treatment in NPY-stained 
sections. Immunostaining was rated 0 to 5 using a scale adapted from methods of mossy 
fibre sprouting assessment33. Score 0, no NPY between the tips and crest of the dentate 
gyrus; Score 1, sparse staining in the supragranular region in a patchy distribution between 
the tips and crest of the dentate gyrus; Score 2, more abundant NPY in the supragranular 
region in a continuous distribution between tips and crest of the dentate gyrus; Score 3, 
prominent NPY in the supragranular region in a continuous pattern between tips and crest, 
with occasional patches of confluent staining between tips and crest of the dentate gyrus; 
Score 4, prominent NPY in the supragranular region that form a confluent dense laminar 
band between tips and crest; Score 5, confluent dense laminar band of NPY in the 
supragranular region that extends into the inner molecular layer. 
miRNA expression 
Total RNA was extracted using the miRNeasy kit (Qiagen) and 250 ng reverse transcribed 
using stem-loop Multiplex primer pools (Applied Biosystems). We used RT specific primers 
for mouse miRNAs miR-19a and miR-134 (Applied Biosystems) and qPCRs were carried 
out on a 7900HT Fast Realtime System (Applied Biosystems) using Taqman microRNA 
assays (Applied Biosystems). RNU19 or U6B was used for normalization. A relative fold 
change in expression of the target gene transcript was determined using the comparative 
cycle threshold method (2 -AACT) 
Western blotting 
Protein was extracted from whole hippocampus or individual microdissected CA3 subfields, 
subjected to SDS-PAGE, transferred to nitrocellulose membranes and incubated with the 
following primary antibodies: Limkl (1:1,000, Cat. 3842) and CREB (1:1,000, clone 
86B10) (both from Cell Signaling Technology), p-Actin (1:2,000, clone AC40, Sigma-
Aldrich), a-Tubulin (1:2,000, sc-8035) and GFP (1:500, sc-9996) (both from Santa Cruz 
Biotechnology). Membranes were then incubated with horseradish peroxidase-conjugated 
secondary antibodies (Jackson ImmunoResearch) and bands visualized using Supersignal 
West Pico Chemiluminescence Substrates (Pierce). Images were captured using a Fuji-Film 
LAS-300 and densitometry performed using AlphaEaseFC4.0 gel-scanning integrated 
optical density software (Alpha Innotech). 
Argonaute-2 immunoprecipitation 
Pools of three individual CA3 subfields for each condition were homogenized in 
immunoprecipitation buffer (300 mM NaCL, 5 mM MgCl2, 0.1% NP-40, 50 mM Tris HC1 
pH7.5), centrifuged, and then 400 |xl lysate incubated overnight at 4°C with 5 |xg of 
antibodies against Argonaute-2 (C34C6, Cell Signaling Technology). Protein A-agarose 
beads (Santa Cruz Biotechnology) were added, mixed and incubated for 1 h at 4 °C, then 
centrifuged and the supernatant removed. The pellet was washed and processed for miRNA 
extraction, stem-loop reverse transcription and RT-PCR (Applied Biosystems). 
In situ hybridization 
Mice (iz=3) were perfused with 4% paraformaldehyde and 12 |xm tissue sections mounted 
on SuperFrost-Plus slides (VWR). Using RNAse free solutions, slides were washed with 
RIPA buffer (150 mM NaCl, 1% IGEPAL, 0.5% Na deoxycholate, 0.1% SDS, 1 mM 
EDTA, 50 mM Tris pH 8.0) followed by treatment with 0.25% acetic anhydride in 0.1 M 
triethanolamine, rinsed with 0.1% Tween-20 in PBS and treated with 5 |xg mT1 Proteinase 
K. Next, slides were rinsed in hybridization buffer (lx saline solution, 50% formamide and 
IX Denhardt's) for 1 h at 56 °C (melting temperature Tm-20C, Tm provided by Exiqon). 
The probe to detect miR-134 was the reverse complement to the mature miRNA and was 5'-
digoxigenin-labeled,2'-0,4'-C methylene bicyclonucleoside monomer-containing 
oligonucleotide (LNA-modified). Probes were incubated 1:200 in hybridization buffer 
overnight at 56 °C in a humidified chamber. The following day sections were washed in 
FAM buffer (2x SSC, 50% formamide and 0.1% Tween 20) for 1 h at 60 °C. Then sections 
were rinsed in B1 buffer (150 mM NaCl, 100 mM Maleic acid and 0.4% IGEPAL pH:7.5) 
for 1 h at room temperature and B2 buffer (2% blocking reagent and 10% goat serum in B1) 
for 30 min. Polyclonal antibodies against digoxigenin (1:1000, Cat. 11093274910, Roche) 
were incubated in B2 overnight at 4 °C. The following day sections were washed in B1 
buffer and incubated in B3 buffer (100 mM NaCl, 50 mM MgCl2, 0.025% Tween 20 and 
100 mM Trizma pH 9.5) for 30 min. Then 200 |xl of color substrate solution (CSS: Nitroblue 
tetrazolium in BCIP stock solution (Roche) diluted 1:50 in B3 buffer) was added to each 
slide until the signal appeared. Slides were then rinsed, mounted with medium and 
coverslipped. 
Antagomirs 
Scr or Ant-134 (Exiqon, LNA- and 3 '-cholesterol modified oligonucleotides) in artificial 
cerebrospinal fluid (aCSF) (Harvard Apparatus) was injected into the lateral ventricle of the 
mouse. 
Behaviour analysis 
Exploratory activity was assessed in Ant-134 and Scr-injected mice in the open field. Each 
mouse was placed individually in the centre of an open field apparatus (ENV-510; 27.9 x 
27.9 cm; Med Associates). Total ambulatory counts, distance travelled (cm), and vertical 
counts were recorded. Data were collected over a 60 min period. 
Spine density analysis 
Coronal mouse brain sections (150 |xm) were cut on a vibratome and pre-labeled with DAPI. 
Pyramidal cells from the CA3 subfield were individually injected with Lucifer yellow (8% 
in 0.1 M Tris buffer, pH 7.4). Lucifer Yellow was applied to each injected cell by 
continuous current until the individual dendrites of each cell could be traced to an abrupt end 
at their distal tips that fluoresced brightly. Sections were then processed with a rabbit 
polyclonal antibody against Lucifer Yellow produced at the Cajal Institute [1:400,000 in 2% 
bovine serum albumin (A3425; Sigma-Aldrich), 1% Triton X-100, 5% sucrose in phosphate 
buffer] followed by a streptavidin coupled to Alexafluor 488 (1:1000; Molecular Probes). 
The sections were washed and mounted with ProLong Gold Antifade Reagent (Invitrogen). 
For each pyramidal neuron (4-7 neurons from each mouse, 7 mice per group, 83 neurons 
total), 1 randomly selected dendrite was scanned from the soma to the tip. Images of 
dendrites from Scr and Ant-134 mice (n= 40) were acquired with a Zeiss (LSM 710) 
confocal laser scanning microscope and fluorescence of AlexaFluor 488 was recorded. 
Image stacks were obtained that consisted of 10-100 image planes (voxel size, 0.057 x 
0.057 x 0.14 |xm and area 58.36 x 58.36 |xm) with a 63x oil-immersion lens (AN, 1.40; 
refraction index 1.45) using a calculated optimal zoom factor 2.3. For each stack, laser 
intensity and detector sensitivity were set so that the fluorescence signal from the dendritic 
spines occupied the full dynamic range of the detector. Therefore, some pixels were 
saturated in the dendritic shaft, but no pixels were saturated within the dendritic spines. 
After the acquisition, stacks were opened with Imaris 7.1 (Bitplane AG). The images were 
coded and not broken until the quantitative analysis had been completed. After acquisition, 
the stacks were processed with a three-dimensional blind deconvolution algorithm 
(Autodeblur; Autoquant, Media Cybernetics) for 10 iterations to reduce the out-of-focus 
light. Image stacks were imported to the confocal module of Neurolucida 8.03 
(MicroBrightfield, Inc.) and dendritic spine density was determined by tracing the image of 
the acquired dendrites in three dimensions. Spines were marked during tracing and all 
protrusions were considered spines. After tracing the reconstructed data were exported to 
Neurolucida Explorer (MicroBrightField Inc.) for quantitative analysis. The spine density 
was calculated for each dendrite by dividing its length by the number of spines, and the 
spine density was also analyzed as a function of its distance from soma (Sholl analysis) by 
dividing the length of the dendritic segment by the number of spines in this distance for 
every 10 |xm distance from the soma. 
Cell culture 
SH-SY5Y cells were grown in 10% fetal calf serum, 2 mM glutamine and 100 U mT1 
penicillin and streptomycin in Dubelco's Modified Eagle Medium/Ham's F12. Cells were 
maintained at 37 °C in a humidified atmosphere of 5% CO2. Hippocampal neurons were 
prepared from gestational day 18 embryos (E18). The harvested embryos were transferred to 
Hank's balanced salt solution without calcium and magnesium medium (Invitrogen), 
hippocampi isolated, and the surrounding meninges were removed. The tissue was then 
incubated with Papain (Worthington Biochemical Corp.) for 30 min, the cells were gently 
dissociated, counted and then seeded in dishes coated with 1 mg mT1 poly(L-lysine) and 20 
|xg mL1 Laminin in Horse Serum/Neurobasal medium (10% Horse Serum, 2 mM 
Glutamine, 2 mM pyruvate and 100 U ml -1 penicillin/streptomycin in Neurobasal medium). 
After 3 h, the medium was removed and N2/B27/Neurobasal medium (N2 (Invitrogen), B27 
(Invitrogen) 2 mM Glutamine, 2 inM pyruvate and 100 U mT1 penicillin/streptomycin in 
Neurobasal medium) was added. Half of the N2/B27/Neurobasal medium was replaced 
every 2 days. 
Two days after transfection, hippocampal neurons were exposed to 0.3 |xM KA for 6 h and 
then neuronal damage was assessed. Neurons were live-stained with Hoechst 33258 (1 |xg 
mT1) and propidium iodide (5 |xM) in the medium for 30 min. Nuclear morphology was 
assessed with an epifluorescence microscope under 20x objective. For each condition, 
images of nuclei were captured in six different areas for each individual experiment. GFP 
and PI positive cells showing condensed and/or fragmented nuclei were scored as dead and 
expressed as a percentage of the total GFP positive cell population. 
Plasmids and transfection 
SH-SY5Y cells were transfected using lipofectamine 2000 (Invitrogen). Briefly, DNA was 
incubated with the lipofectamine reagent for 20 min in a ratio of 1:2 v/v. Then, the 
DNA:Lipofectamine mix was added to the cells for 4 h. Medium was removed, cells washed 
and new medium was added. Two days later, cells were harvested and samples prepare for 
western blotting. Hippocampal neurons were transfected at DIV6 with 3 |xg of the 
expression plasmid pGFP-V-RS-scramble or pGFP-V-RS -shLimk (Origen) and 0.01 nmol 
of either Scr or Ant-134 (Exiqon) using calcium-phosphate technique. The following 
sequences were used: 
sh-Control:GCACTACCAGAGCTAACTCAGATACTACT 
shLimkl: AAGGACAAGAGGCTCAACTTCATCACTGA 
sh-Limk2: CTGGCACGCAGACTGCTTCAGGTGTTGTG 
Data analysis 
All data are presented as the means ± standard error of the mean (s.e.m). Two group 
comparisons were made using unpaired Student's t-test, while multi-group comparisons 
were made using one or two-way analysis of variance (ANOVA) followed by appropriate 
post hoc testing (GraphPad Instat). Significance was accepted at P< 0.05. 
Supplementary Material 
Refer to Web version on PubMed Central for supplementary material. 
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Figure 1. 
miR-134 up-regulation following SE and in epilepsy, (a) Photomicrographs show neuronal 
death (Fluoro-Jade B, FJB) in CA3 stratum pyramidale (s.p.) 24 h after SE compared to 
control (Cont). Below, depiction of electrographic seizure frequency and amplitude during 
SE. (b) In situ hybridization showing miR-134 in soma of CA3 pyramidal neurons, (c) RT-
qPCR measurement of miR-134 (normalized to RNU19) for CA3 (P= 0.016) and CA1 (P= 
0.035) 24 h after SE (n= 5 per group), (d) Argonaute-2 (Ago2) -immunoprecipitated (IP) 
miR-134 from Cont and SE mice (24 h) (P= 0.035, n=3 per group), (e) Limkl western blot 
(24 h) and densitometry (P= 0.001, n= 5 per group), (f) Photomicrographs showing loss of 
CA3 neurons (NeuN, arrows) and astrogliosis (GFAP) in epileptic mice 14 days after SE 
and (below) a telemetry-recorded spontaneous seizure, (g) miR-134 levels in epileptic mice 
for CA3 (1 week, P= 0.806; 3 weeks, P= 0.049) and CA1 (1 week, P= 0.003; 3 weeks, P= 
0.008) (n=5 per group), (h) Western blot shows Limkl levels 1 and 3 weeks after SE and 
densitometry (P= 0.028; n= 4 per group), (i) miR-134 levels in temporal lobe samples from 
individuals with TLE compared to autopsy controls (Cont) (P= 0.029; n=3 per group). 
Western blot (above) shows LIMK1 levels (Unpaired Mest, P= 0.039, n=3 per group, not 
shown). Scale bars, 200|xm. *P< 0.05, **p< 0.01 compared to Cont. 
Figure 2. 
Antagomir-mediated silencing of miR-134 in mouse hippocampus, (a-b) RT-qPCR 
measurement of a) miR-134 (P< 0.001) and b) miR-19a (P= 0.363) in hippocampus 24 h 
after i.c.v. injection of miR-134-targeting antagomir (Ant-134) or a non-targeting control 
(Scr). ***p< 0.001 compared to artificial cerebrospinal fluid (aCSF); #mp< 0.001 
compared to Scr (n=3 per group), (c) miR-134 levels in hippocampus after injection of 
Ant-134 or Scr at 1 d (P= 0.005), 3 d (P= 0.01), 5 d (P= 0.001), 7 d (P= 0.004), 1 month 
(P= 0.034) and 2 months (P= 0.469) later. *P< 0.05; **P< 0.01; NS, non-significant (n = 
3-4 per group), (d) NeuN counts at two different levels of the dorsal hippocampus in 
animals injected 24 h earlier with either Scr or Ant-134 (rostral, P= 0.585; medial, P= 
0.387) (n= 4 per group), (e) NeuN staining of the CA3 subfield 24 h after injection of Scr or 
Ant-134. Scale bar: e, 200 |xm. (f) Behavioral analysis of mice injected 24 h earlier either 
with Scr or Ant-134. Graph shows indices of exploratory activity: total ambulatory counts (P 
= 0.310); distance travelled (cm) (P= 0.320); vertical counts (P= 0.300). 
a b 
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Figure 3. 
Antagomir silencing of miR-134 reduces hippocampal CA3 spine density in vivo, (a) Field 
view of hippocampus showing Lucifer yellow-injected CA3 neurons (green) and nuclei 
(DAPI, blue), (b) Higher magnification of (a) showing injected CA3 neurons, (c) 
Photomicrographs of the basal tree from Lucifer yellow-injected animals treated with either 
Scr or Ant-134 24 h earlier, (d) Representative images of individual dendrites from four 
individual animals injected with Scr (left panels) or Ant-134 (right panels), (e) Spine density 
as a function of the distance from the soma (ShoU Analysis) for Scr and Ant-134 animals, (f) 
Spine density in Scr and Ant-134 mice (P= 0.037; *P< 0.05 compared to Scr, n=l per 
group). Scale bars: a, 500 |xm; b, 100 |xm; c, 20 |xm. d, 12 |xm. 
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Figure 4. 
Antagomir silencing of miR-134 reduces seizure severity during SE. (a) Graphs show 
HAHFDs (P= 0.0051) and total EEG power (P= 0.033) during SE in animals injected 24 h 
earlier with Scr or Ant-134. *P<0.05, **P<0.01 compared to Scr (n= 4-8 per group), (b) 
Total EEG power and (c) frequency and amplitude parameters during SE from 
representative Scr- and Ant-134 injected animals covering the period between KA injection 
and anticonvulsant administration, (d) miR-134 levels in Scr and Ant-134 animals 24 h after 
SE (P= 0.0078, n= 4). **p< 0.01 compared to Scr. (e) Limkl protein levels in non-seizure, 
Scr-injected (Scr + C) and after SE in mice given Scr (Scr + SE) or Ant-134 (Ant + SE) (n = 
1 per lane). Graph shows Limkl levels normalized to actin (Scr + C compared to Scr + SE, 
P= 0.007; Scr vs Ant-134 after SE (P= 0.018; Scr + C compared to Ant-134 + SE, P= 
0.270). **P< 0.01 compared to Scr + C; §P< 0.05 compared to Ant-134 + SE) (n = 4 per 
group). 
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Figure 5. 
Antagomir silencing of miR-134 protects against SE in vivo and KA toxicity in vitro, (a-f) 
Graphs and photomicrographs (dorsal hippocampus) 24 h after SE in mice given Scr or 
Ant-134 showing (a, b) FJB counts (rostral, P< 0.001; medial, P< 0.001), (c, d) TUNEL 
counts (rostral, P= 0.001; medial, P= 0.001), (e, f) NeuN counts (rostral, P< 0.001, medial, 
P= 0.009).**P< 0.01, ***p< 0.001 compared to Scr (n= 4-8 per group). Scale bars, 200 
|xm. (g) miR-134 levels in primary hippocampal neurons 24 h after KA (0.3 |xM) (P= 
0.019). *P< 0.05, n= 3 per group, (h) Western blots show Limkl and GFP in SH-SY5Y 
cells transfected with shControl (Con) or different short interfering RNAs targeting Limkl 
(shLimkl/2). shLimk2 reduced Limkl by -48% (average of two experiments), (i) 
Percentage cell death induced by KA in hippocampal neurons (ratio of propidium iodide (PI) 
positive-GFP positive neurons over GFP-positive), and effect of Scr or Ant-134 in cells co-
transfected with either Con or Limk shRNA. Cell death in non-transfected neurons in either 
group averaged 30 ± 12% (data not shown). shCon/Scr compared to shCon/Ant-134, P= 
0.005; shLimk/Scr compared to shCon/Ant-134, P= 0.004; shCon/Ant-134 compared to 
shLimk/Ant-134, P= 0.001). **p< 0.01, n= 4 per group, (j) Photomicrographs of 
hippocampal neurons in each condition. Arrows (and see inset) indicate dead cells positive 
for both GFP (green) and PI (red). Scale bar, 50 |xm. 
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Figure 6. 
Antagomir silencing of miR-134 reduces post-SE epileptic seizures and protects against 
progressive TLE pathology. (a,b) Graphs show a) KA-triggered seizures (P= 0.589) and b) 
CA3 damage at 24 h (P= 0.541) between Ant-134 and Scr groups when the antagomirs were 
injected 1 h after inducing SE (n = 4-5 per group), (c) FJB staining 24 h after SE in mice 
injected 1 h after KA with Scr or Ant-134. (d) Graphs show telemetry-detected spontaneous 
seizures for individual animals during the two weeks following SE for (left) Scr and (right) 
Ant-134 mice, (e) Daily epileptic seizures in Scr and Ant-134 animals (P= 0.036; n= 5 per 
group), (f) Hippocampal NeuN (arrows indicate neuron loss) and GFAP (astrogliosis) 
staining in Scr and Ant-134 mice after two weeks epilepsy monitoring. Graph to the right 
shows NeuN counts in dorsal hippocampus (rostral, P= 0.024, medial, P= 0.02) (*P< 0.05, 
n= 5 per group), (g) Neuropeptide Y (NPY) score in epileptic animals (P= 0.008, n=5 per 
group) and (right) representative NPY-stained sections from Scr and Ant-134 mice after two 
weeks epilepsy monitoring. Scale bars: f, 200|xm; c, g, 1 mm. (h) Graphs show the number 
of generalized tonic-clonic seizures (GTCS) each day for individual animals during two 
periods of five days continuous video monitoring following SE for (left) Scr and (right) 
Ant-134 mice, (i) Total GTCS counts averaged from the two monitoring periods (**p= 
0.003, n= 5-6 per group). 
